Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Cont...( - Barr Plans to Launch Generic Y...),Health

- Barr Plans to Launch Generic Yasmin(R) on or before July 1, 2008

- Barr Plans to Launch Generic Yaz(R) on or before July 1, 2011

- Bayer to Continue Appeal of Yasmin(R) District Court Decision

MONTVALE, N.J., June 24 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its wholly owned subsidiary, Barr Laboratories, Inc. has entered into supply and licensing agreements with Bayer for generic versions of Bayer's Yasmin(R) (drospirenone and ethinyl estradiol) and Yaz(R) (drospirenone and ethinyl estradiol) oral contraceptive products. Under terms of these agreements, Bayer will supply Barr with the generic products for launch prior to the expiration of the patents protecting these products and Barr will have sole responsibility to market, sell and distribute the products in the U.S. under the Barr Laboratories label.

"We are very pleased to have reached these licensing agreements with Bayer that permit Barr to launch our authorized generic versions of Yasmin and Yaz to patients years before the patents protecting these products are due to expire," said Bruce L. Downey, Barr's Chairman and CEO. "Although Bayer will continue to appeal the March 3, 2008 decision by U.S. District Court for the District of New Jersey that found the Yasmin patent invalid, these agreements ensure that we will be able to continue selling our generic versions of Yasmin and Yaz regardless of the outcome of that appeal."

Yasmin Supply and Licensing Agreement

Under the Yasmin agreement, Bayer will supply Barr with an authorized generic version of Yasmin for launch on or before July 1, 2008 -- several years earlier than the last-to-expire Bayer patent listed in the U.S. Food and Drug Administ
'/>"/>